Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 09:18 am Sale |
2024-12-31 | 13G | VTEX VTEX |
Polar Capital Holdings Plc | 5,232,020 2.840% |
-5,306,653 (-50.35%) |
Filing History |
| 2025-02-14 09:17 am Sale |
2024-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Polar Capital Holdings Plc | 2,389,668 4.890% |
-298,129 (-11.09%) |
Filing History |
| 2024-11-13 6:01 pm Purchase |
2024-09-30 | 13G | Bruker Corporation BRKR |
Polar Capital Holdings Plc | 317,928 0.210% |
317,928 (New Position) |
Filing History |
| 2024-11-13 6:00 pm Sale |
2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX |
Polar Capital Holdings Plc | 2,711,163 4.090% |
-424,708 (-13.54%) |
Filing History |
| 2024-11-13 5:58 pm Sale |
2024-09-30 | 13G | Avadel Pharmaceuticals plc AVDL |
Polar Capital Holdings Plc | 4,803,899 4.990% |
-1,947,883 (-28.85%) |
Filing History |
| 2024-11-13 5:57 pm Purchase |
2024-09-30 | 13G | VTEX VTEX |
Polar Capital Holdings Plc | 10,538,673 5.700% |
10,538,673 (New Position) |
Filing History |
| 2024-11-13 5:56 pm Purchase |
2024-09-30 | 13G | Hagerty, Inc. HGTY |
Polar Capital Holdings Plc | 5,002,477 5.570% |
5,002,477 (New Position) |
Filing History |
| 2024-11-13 5:55 pm Purchase |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
Polar Capital Holdings Plc | 2,687,797 5.690% |
2,687,797 (New Position) |
Filing History |
| 2024-02-13 09:41 am Purchase |
2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Polar Capital Holdings Plc | 3,135,871 5.730% |
3,135,871 (New Position) |
Filing History |
| 2024-02-13 09:40 am Purchase |
2023-12-31 | 13G | Avadel Pharmaceuticals plc AVDL |
Polar Capital Holdings Plc | 6,751,782 7.510% |
3,957,109 (+141.59%) |
Filing History |
| 2024-02-13 09:39 am Purchase |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Polar Capital Holdings Plc | 500,000 1.050% |
500,000 (New Position) |
Filing History |
| 2024-02-13 09:39 am Sale |
2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Polar Capital Holdings Plc | 3,169,239 3.600% |
-1,679,394 (-34.64%) |
Filing History |
| 2024-02-13 09:27 am Purchase |
2023-12-31 | 13G | NanoString Technologies, Inc. NSTGQ |
Polar Capital Holdings Plc | 3,975,000 8.260% |
196,269 (+5.19%) |
Filing History |
| 2024-02-13 09:26 am Sale |
2023-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
Polar Capital Holdings Plc | 6,297,688 6.670% |
-820,256 (-11.52%) |
Filing History |
| 2023-11-16 1:13 pm Purchase |
2023-10-20 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
Polar Capital Holdings Plc | 7,117,944 7.560% |
7,117,944 (New Position) |
Filing History |
| 2023-07-28 09:01 am Purchase |
2023-07-19 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Polar Capital Holdings Plc | 157,448 5.020% |
157,448 (New Position) |
Filing History |
| 2023-07-13 1:43 pm Unchanged |
2022-12-31 | 13G | NanoString Technologies, Inc. NSTGQ |
Polar Capital Holdings Plc | 3,778,731 8.100% |
0 (Unchanged) |
Filing History |
| 2023-02-14 4:03 pm Sale |
2022-12-31 | 13G | Summit Therapeutics Inc. SMMT |
Polar Capital Holdings Plc | 0 0.000% |
-6,295,713 (Position Closed) |
Filing History |
| 2023-02-14 4:02 pm Purchase |
2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Polar Capital Holdings Plc | 4,848,633 5.900% |
4,848,633 (New Position) |
Filing History |
| 2023-02-14 4:01 pm Sale |
2022-12-31 | 13G | Quotient Limited QTNT |
Polar Capital Holdings Plc | 0 0.000% |
-231,291 (Position Closed) |
Filing History |